Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring
Launched by CENTRE HOSPITALIER RÉGIONAL METZ-THIONVILLE · Mar 7, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a way to make children more comfortable during a specific medical imaging test called a brain MRI. Researchers want to see if a special scoring system, which looks at brain activity using a test called an electroencephalogram (EEG), can help determine if a lower dose of a sedative medication called dexmedetomidine (DEX) is enough for some children. If the score shows that a child may need more sedation to feel calm and relaxed during the MRI, the study will provide a higher dose of DEX.
To be part of this trial, children must be between 12 months and 18 years old and need DEX sedation for their MRI. The study is looking for children who may have trouble cooperating during the procedure, like those with autism or previous unsuccessful MRIs. Parents or guardians will be asked to give their permission for their child to participate. Throughout the trial, participants will receive careful monitoring to ensure their safety and comfort during the MRI process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Indication of DEX sedation for brain NMRI at the CHR de Metz-Thionville
- • in a patient aged between 12 months and 5 years or
- • for a patient aged between 5 and 18 whose cooperation during the examination appears compromised (previous failure, autism spectrum disorders, etc.).
- • Membership of a social security scheme
- • Free and informed consent obtained from the patient's legal guardian(s).
- Exclusion Criteria:
- • Weight \< 10 kg
- • Patients with contraindications to the use of DEX
- • Hypersensitivity to the active ingredient or to any of the excipients listed in the section on "Hypersensitivity".
- • Advanced heart block (level 2 or 3), unless pacemaker implanted
- • Uncontrolled hypotension
- • Acute cerebrovascular pathologies
- • Patients with nasal obstruction
- • Parental refusal of DEX administration
- • Minors under guardianship
- • Minors under judicial sanction
About Centre Hospitalier Régional Metz Thionville
The Centre Hospitalier Régional Metz-Thionville is a leading healthcare institution in the Grand Est region of France, dedicated to delivering high-quality medical care and advancing clinical research. With a multidisciplinary team of experienced healthcare professionals, the center emphasizes patient-centered services and innovative treatment approaches. Committed to enhancing medical knowledge and improving patient outcomes, the hospital actively participates in clinical trials across various therapeutic areas, fostering collaboration with academic institutions and industry partners to drive advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Metz, , France
Patients applied
Trial Officials
Anne-Charlotte CULLIER, MD
Principal Investigator
CHR Metz Thionville Hopital Femme Mère Enfant
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported